Juy-108 [better]

A that potently and selectively inhibits both VEGFR‑2 and TIE2 can achieve continuous target suppression , provide patient convenience , and enable combination regimens with oral ICIs or targeted agents.

As a mid-2010s release, it reflects the industry's shift toward high-definition (HD) standards as the baseline for production. Starring Performer: Hana Haruna juy-108

Current status (Q1 2026):